Intec Pharma Ltd. (NTEC) Upgraded by Zacks Investment Research to Hold

Intec Pharma Ltd. (NASDAQ:NTEC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday.

According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “

A number of other equities analysts have also recently issued reports on the company. CIBC restated an “outperform” rating and issued a $15.00 target price (up from $10.00) on shares of Intec Pharma in a report on Thursday, September 21st. Oppenheimer Holdings, Inc. lifted their target price on Intec Pharma from $10.00 to $15.00 and gave the stock an “outperform” rating in a report on Thursday, September 21st. Finally, Roth Capital set a $10.00 target price on Intec Pharma and gave the stock a “buy” rating in a report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $12.25.

Shares of Intec Pharma (NASDAQ:NTEC) opened at 8.70 on Wednesday. The firm has a 50-day moving average price of $8.63 and a 200 day moving average price of $8.63. The firm’s market cap is $119.52 million. Intec Pharma has a 12-month low of $4.20 and a 12-month high of $9.80.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Markets Daily and is owned by of Markets Daily. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.themarketsdaily.com/2017/10/11/intec-pharma-ltd-ntec-upgraded-by-zacks-investment-research-to-hold.html.

A hedge fund recently raised its stake in Intec Pharma stock. Migdal Insurance & Financial Holdings Ltd. increased its holdings in shares of Intec Pharma Ltd. (NASDAQ:NTEC) by 5.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 522,200 shares of the biotechnology company’s stock after buying an additional 25,000 shares during the quarter. Migdal Insurance & Financial Holdings Ltd. owned 3.80% of Intec Pharma worth $2,977,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 16.41% of the company’s stock.

About Intec Pharma

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Receive News & Ratings for Intec Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply